XTLB stock forecast, quote, news & analysis
XTL Biopharmaceuticals Ltd is an intellectual property-based company focused on the development, management, and commercialization of intellectual property... Show more
Why XTL Biopharmaceuticals (XTLB) Stock Is Down -21.7% in the Last 30 Days
Key Takeaways
- XTL Biopharmaceuticals (XTLB) shares fell roughly 21.7% over the last 30 days, declining from about $1.98 to $1.55 per share.
- The pullback extends a broader downtrend, with the stock down approximately 45% over the last quarter.
- As a thinly traded micro-cap with no meaningful revenue, XTLB is highly sensitive to shifts in sentiment and low trading volume.
- A Nasdaq staff delisting determination received in May 2026 continues to weigh on investor confidence.
- The company's completed acquisition of Psyga Bio Ltd. marked a strategic pivot toward psychedelic therapeutics, adding uncertainty to its pipeline narrative.
- For deeper detail on valuation, results, and expectations, explore Price Targets, Earnings, and Forecast pages for XTLB.
- To see how automated systems are navigating this and other tickers, explore Trending AI Robots.
XTL Biopharmaceuticals (XTLB) Company Overview and Market Position
XTL Biopharmaceuticals Ltd. is an Israel-based biopharmaceutical company engaged in the acquisition and development of pharmaceutical drug candidates. Its lead asset, hCDR1, is a Phase II-ready compound being evaluated for the treatment of systemic lupus erythematosus (SLE) and Sjögren's syndrome. The company holds a licensing agreement with Yeda Research and Development Company Limited covering the research, development, and commercialization of hCDR1.
In mid-2026, XTL completed the acquisition of Psyga Bio Ltd., shifting its strategic focus toward psychedelic therapies and positioning the company around a psychedelic biotechnology platform. The company operates with a small team and generates no meaningful revenue, and its Nasdaq-listed shares trade as a micro-cap with notably thin liquidity. Investors follow XTLB primarily for its clinical pipeline potential and corporate developments rather than for current financial performance.
XTL Biopharmaceuticals (XTLB) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, XTLB declined from a closing price of approximately $1.98 to $1.55, a drop of about 21.7%. The move was characterized by persistent downward pressure and elevated daily volatility, with intermittent rebounds that failed to hold.
The one-month slide is part of a longer decline. Measured from the beginning of August, when shares traded near $2.81, the stock has fallen roughly 45% over the last quarter. The trend has been broadly lower, punctuated by short-lived rallies rather than any sustained recovery, reflecting continued selling in a low-liquidity name.
What Drove XTLB Stock Price in the Last 30 Days
The recent decline in XTLB shares has been driven less by a single discrete event and more by a combination of structural pressures. As a micro-cap with limited trading volume, the stock is vulnerable to outsized moves on relatively small order flow, and the prevailing direction over the past month has been downward.
The Nasdaq staff delisting determination announced in May 2026 remains a key overhang, keeping a cloud over the stock's exchange listing and discouraging risk-averse investors. The company's pivot to psychedelic therapeutics following the Psyga Bio acquisition has also introduced strategic uncertainty, as investors weigh an early-stage, capital-intensive platform against a business that generates little revenue. With no fresh clinical or financial catalysts emerging in the period, selling pressure persisted and the stock drifted toward its 52-week low.
What Drove XTLB Stock Performance Over the Last Quarter
The roughly 45% decline over the last quarter reflects a broader reassessment of XTLB's risk profile. The stock has been under pressure since the disclosure of the Nasdaq delisting determination and the announcement of an American depositary shares (ADS) ratio change earlier in the year, both of which raised questions about listing compliance and share structure.
The completed Psyga Bio acquisition redirected the company's strategy toward psychedelic biotechnology, a transition that typically brings elevated execution risk and a longer timeline to potential commercialization. Combined with the absence of revenue and ongoing net losses, these factors have kept sentiment negative and driven a multi-month downtrend that the last 30 days extended.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots drawn from a broader universe of hundreds of bots trading thousands of tickers. Only the top-performing and most relevant bots are surfaced in this section, allowing users to review strategies that span different timeframes, approaches, and performance metrics. The page is designed to help traders compare automated strategies and identify those that align with their own objectives. Exploring the section can provide a useful perspective on how algorithmic systems are positioning across the market.
XTLB Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important factors for XTLB center on its exchange listing status and its ability to advance its repositioned pipeline. Investors will likely monitor any updates regarding the Nasdaq delisting process and whether the company can demonstrate compliance. Progress on the psychedelic platform acquired through Psyga Bio, along with any developments related to hCDR1, will also be closely watched.
Additional considerations include the company's cash position and financing capacity, given its lack of revenue and ongoing losses, as well as broader investor appetite for speculative micro-cap biotech names. Macroeconomic conditions and sector-wide sentiment toward clinical-stage biotechnology may further influence trading in a stock this thinly capitalized. These factors should be evaluated alongside the inherent risks of small-cap biotech investing.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for XTLB turns negative, indicating new downward trend
XTLB saw its Momentum Indicator move below the 0 level on October 26, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 124 similar instances where the indicator turned negative. In 113 of the 124 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for XTLB turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 45 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XTLB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for XTLB entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +10.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where XTLB advanced for three days, in 120 of 158 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
XTLB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: XTLB's P/B Ratio (-81.044) is slightly lower than the industry average of (3.498). P/E Ratio (-0.484) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.100) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (6.083) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. XTLB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XTLB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics to treat hepatitis and other infectious diseases, using human antibodies and synthetic chemicals
Industry Biotechnology